1FW2e8F
1FW2e8F
1FW2e8F
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
SECTION 1 2 3<br />
TIME TO ACT<br />
• Ensure that women’s health needs are prioritized, sexual and reproductive<br />
rights are upheld, and that bilateral aid is not permitted to constrain<br />
women’s access to reproductive health services.<br />
Corporations should agree to:<br />
• Stop lobbying for the privatization of vital public services, including<br />
healthcare and education;<br />
• Work with government efforts to regulate private healthcare providers<br />
to ensure their positive contribution to Universal Health Coverage.<br />
7) CHANGE THE GLOBAL SYSTEM FOR RESEARCH<br />
AND DEVELOPMENT (R&D) AND FOR PRICING OF<br />
MEDICINES, TO ENSURE ACCESS FOR ALL TO<br />
APPROPRIATE AND AFFORDABLE MEDICINES<br />
Relying on intellectual property as the only stimulus for R&D keeps the<br />
monopoly on making and pricing medicines in the hands of big pharmaceutical<br />
companies. This endangers lives and leads to a wider gap between rich<br />
and poor.<br />
Governments and international institutions should agree to:<br />
• Agree a global R&D treaty which makes public health – not commercial<br />
interest – the decisive factor in financing R&D;<br />
• Allocate a percentage of their national income to scientific research,<br />
including R&D for medicines;<br />
• Exclude strict intellectual property rules from trade agreements and refrain<br />
from all measures that limit government’s policy space to implement<br />
public health measures and increase their access to medicine, medical<br />
technologies, knowledge, health and education services;<br />
• Break monopolies and encourage affordable pricing of medicines via<br />
generic competition;<br />
• Scale-up investment in national medicine policy development and drug<br />
supply chains.<br />
Pharmaceutical companies should agree to:<br />
• Be transparent about the cost of R&D, and look for new ways to finance R&D<br />
beyond intellectual property;<br />
• Stop national and international lobbying for private corporate gains at the<br />
expense of public health.<br />
119